Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL)

82.02
Delayed Data
As of Dec 11
 +0.45 / +0.55%
Today’s Change
13.09
Today|||52-Week Range
101.00
+450.47%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.0B

Company Description

Madrigal Pharmaceuticals, Inc. clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel compounds for the treatment of cardiovascular, metabolic and liver diseases. The company offers MGL-3196, an orally administered, small-molecule liver-directed ß-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Madrigal Pharmaceuticals was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Contact Information

Madrigal Pharmaceuticals, Inc.
500 Office Center Drive
Fort Washington Pennsylvania 19034
P:(610) 527-6790
Investor Relations:

Employees

Shareholders

Mutual fund holders7.82%
Individual stakeholders13.71%
Other institutional12.77%

Top Executives

Paul A. FriedmanChairman, President & Chief Executive Officer
Marc R. SchneebaumChief Financial Officer & Senior Vice President
Rebecca A. TaubDirector & Chief Medical Officer